Novo Nordisk shares fall
Novo Nordisk cut its full-year earnings outlook after reporting weaker-than-expected quarterly sales of its popular weight-loss drug Wegovy, raising concerns among investors about growing competition from Eli Lilly. The results end a prolonged run of positive earnings news from Europe’s most valuable listed company.
ENTRADAS POPULARES
UK sets new climate target for 2035
noviembre 13, 2024
Children go back to school after Valencia floods
noviembre 13, 2024
Researchers document huge decline in African elephants
noviembre 13, 2024
Mission: Impossible 8 title revealed
noviembre 13, 2024
TRANSMISIÓN EN VIVO